Skip to content

    UroGen Pharma (URGN) stock price & financials

    View URGN earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance+123.2% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $25.20M
    $24.57M
    $20.25M
    $24.21M
    $27.48M
    +9.0%
    $37.84M
    +54.0%
    $50.96M
    +151.6%
    $72.46M
    +199.2%
    Strengthening
    Operating Profit
    -$17.55M
    -$27.66M
    -$36.91M
    -$41.45M
    -$27.39M
    -56.1%
    -$19.11M
    +30.9%
    -$20.26M
    +45.1%
    $111.0K
    Strengthening
    Net Profit
    -$23.67M
    -$37.51M
    -$43.84M
    -$49.94M
    -$33.35M
    -40.9%
    -$26.36M
    +29.7%
    -$23.57M
    +46.2%
    -$14.35M
    +71.3%
    Strengthening
    EPS
    $-0.51
    $-0.80
    $-0.92
    $-1.05
    $-0.69
    -35.3%
    $-0.47
    +48.9%
    $-0.28
    +73.3%
    Strengthening
    Other Income
    -$158.0K
    -$62.0K
    -$90.0K
    -$378.0K
    -$197.0K
    -24.7%
    -$5.0K
    +91.9%
    -$323.0K
    -258.9%
    -$347.0K
    +8.2%
    Weakening
    Interest
    Depreciation
    Profit before Tax
    -$23.58M
    -$34.86M
    -$43.45M
    -$48.92M
    -$34.40M
    -45.9%
    -$26.64M
    +23.6%
    -$28.35M
    +34.8%
    -$8.72M
    +82.2%
    Strengthening
    MarginsOPM
    -69.6%
    -112.6%
    -182.3%
    -171.2%
    -99.7%
    -43.2%
    -50.5%
    +55.1%
    -39.8%
    +78.2%
    0.1%
    Strengthening
    Tax
    -0.4%
    -7.6%
    -0.9%
    -2.1%
    3.1%
    1.0%
    16.8%
    -64.5%
    -3017.9%
    Weakening
    ReturnsROIC
    2.4%
    3.8%
    4.4%
    5.0%
    3.3%
    +40.9%
    2.6%
    -29.7%
    2.4%
    -46.2%
    1.4%
    -71.3%
    Weakening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$101.32M$49.69M$52.86M$44.36M$55.41M$95.00M$171.99M$110.75M$79.13M
    Short-Term Investments
    Total Current Assets$102.24M$148.63M$115.62M$114.39M$128.91M$169.19M$276.13M$186.02M$235.43M
    Net PP&E$948.0K$4.71M$4.20M$3.15M$3.75M$689.0K$1.50M$3.72M$3.41M
    Goodwill
    Intangibles
    Total Assets$103.56M$202.39M$122.00M$119.75M$135.62M$178.31M$285.71M$200.46M$252.59M
    LiabilitiesTotal Current Liabilities$13.46M$19.48M$21.44M$22.38M$23.92M$31.21M$45.95M$46.42M$61.91M
    Short-Term Debt
    Long-Term Debt$0$97.54M$98.55M$121.73M$122.21M$188.73M
    Long-Term Leases$2.60M$1.50M$398.0K$1.59M$0$58.0K$2.65M$2.36M
    Total Liabilities$13.46M$22.09M$25.65M$111.33M$224.98M$243.52M$294.51M$305.93M$384.99M
    EquityCommon Stock & APIC$44.0K$57.0K$60.0K$61.0K$63.0K$89.0K$115.0K$133.0K$135.0K
    Retained Earnings-$122.87M-$228.02M-$356.50M-$467.32M-$577.10M-$679.35M-$806.22M-$959.72M-$997.64M
    Total Equity$90.09M$180.30M$96.36M$8.41M-$89.36M-$65.21M-$8.80M-$105.47M-$132.40M
    HighlightsNet Cash / (Debt)

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating-$37.33M-$71.02M-$105.89M-$84.89M-$87.56M-$76.38M-$96.77M-$162.44M-$158.92M
    Cash from Investing$35.29M-$145.59M$93.24M$4.07M$1.06M-$953.0K-$20.61M$61.56M$40.10M
    Cash from Financing$66.42M$165.25M$16.53M$72.32M$97.13M$116.93M$194.62M$39.92M$105.29M
    SummaryCapital Expenditure-$560.0K-$325.0K-$1.22M-$752.0K-$254.0K-$194.0K-$295.0K-$289.0K-$218.0K
    Free Cash Flow-$37.89M-$71.34M-$107.10M-$85.64M-$87.81M-$76.57M-$97.06M-$162.73M-$159.13M
    FCF Margin-3359.4%-396344.4%-907.7%-178.3%-136.4%-92.6%-107.4%-148.2%-84.3%

    Ratios